Travere Therapeutics, Inc.

Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun

Vera Therapeutics reported 36-week results on June 2 from the ORIGIN Phase III clinical trial of its B-cell modulator atacicept in the treatment of immunoglobulin A nephropathy (IgAN) in adults, showi

Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it

In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg